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ABSTRACT
The production of recombinant proteins such as the fibroblast growth factors (FGFs)
is the key to establishing their function in cell communication. The production of
recombinant FGFs in E. coli is limited, however, due to expression and solubility
problems. HaloTag has been used as a fusion protein to introduce a genetically-
encoded means for chemical conjugation of probes. We have expressed 11 FGF
proteins with an N-terminal HaloTag, followed by a tobacco etch virus (TEV)
protease cleavage site to allow release of the FGF protein. These were purified by
heparin-aﬃnity chromatography, and in some instances by further ion-exchange
chromatography. It was found that HaloTag did not adversely aﬀect the expression of
FGF1 and FGF10, both of which expressed well as soluble proteins. The N-terminal
HaloTag fusion was found to enhance the expression and yield of FGF2, FGF3 and
FGF7. Moreover, whereas FGF6, FGF8, FGF16, FGF17, FGF20 and FGF22 were
only expressed as insoluble proteins, their N-terminal HaloTag fusion counterparts
(Halo-FGFs) were soluble, and could be successfully purified. However, cleavage of
Halo-FGF6, -FGF8 and -FGF22 with TEV resulted in aggregation of the FGF protein.
Measurement of phosphorylation of p42/44 mitogen-activated protein kinase and of
cell growth demonstrated that the HaloTag fusion proteins were biologically active.
Thus, HaloTag provides a means to enhance the expression of soluble recombinant
proteins, in addition to providing a chemical genetics route for covalent tagging of
proteins.
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INTRODUCTION
Of the 18 receptor-binding fibroblast growth factors (FGF), 15 also bind a heparan sulfate
co-receptor and are classed as growth factors and morphogens. These are grouped into
5 subfamilies based on their protein sequence similarity (Itoh, 2007; Ornitz, 2000), and
they regulate a myriad of processes in development, homeostasis and in some diseases
(Beenken &Mohammadi, 2009; Turner & Grose, 2010). Recombinant FGFs provide a key
tool to study their structure–function relationships, and labelling FGFs for microscopy
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has been important in probing the mechanisms of, for example, their transport (Duchesne
et al., 2012; Lin, 2004; Yu et al., 2009). Chemical labelling has disadvantages compared
to genetically encoded labelling, since with the latter it is easier to predict the structural
and hence functional consequences of labelling, which can be achieved both in vitro
and in vivo. While fluorescent proteins remain a mainstay of genetic labelling, they have
limitations. These have been overcome, for example, by non-covalent tagging of proteins
on hexahistidine sequences with Tris-Ni2+ nitriloacetic acid (Huang et al., 2009; Lata
et al., 2005; Tinazli et al., 2005), which has allowed diverse labelling strategies, ranging
from fluorescent dyes (Uchinomiya et al., 2009) and quantum dots (Roullier et al., 2009;
Susumu et al., 2010) to gold nanoparticles (Duchesne et al., 2008). However, non-covalent
coupling is reversible and exchange may occur in this instance with histidine-rich patches
on endogenous proteins.
HaloTag is a mutant of a bacterial haloalkane dehalogenase, which reacts with
chloroalkane ligands to form a covalent bond that represents the covalent intermediate
of the enzyme’s normal catalytic cycle (Los et al., 2008). Fluorescent dyes (Los et al., 2008)
and quantum dots (Zhang et al., 2006b) carrying a chloroalkane group have been used
to label HaloTag fusion proteins for fluorescence imaging. This approach is particularly
versatile, since it combines the power of a genetically encoded tag (the HaloTag protein)
with covalent labelling.
Consequently, we set out to produce N-terminal HaloTag fusions of diﬀerent FGFs. In
the course of this work, we observed that the N-terminal HaloTag fusion had a substantial
eﬀect on the expression of the more recalcitrant FGFs, consistent with the observation that
HaloTag is a potential solubilisation tag for recombinant proteins (Ohana et al., 2009).
Thus, whereas expression of FGF1 and FGF10 was somewhat reduced and that of FGF2
increased, expression of FGF7, which can be toxic (Ron et al., 1993), was no longer so,
while expression of soluble FGF3, FGF6, FGF7, FGF8, FGF16, FGF17, FGF20 and FGF22
was markedly enhanced. This is in contrast to previous reports where FGFs such as FGF6
(Pizette et al., 1991), FGF8 (Loo & Salmivirta, 2002;Macarthur et al., 1995;Vogel, Rodriguez
& IzpisuaBelmonte, 1996), FGF16 (Danilenko et al., 1999) and FGF20 (Jeﬀers et al., 2002;
Kalinina et al., 2009) have been found to be mainly expressed in inclusion bodies, even as
truncated proteins, and so require refolding. Thus, HaloTag provides not just a means to
label proteins covalently and specifically, but is also a useful solublisation partner for the
production of recombinant proteins.
MATERIALS AND METHODS
Materials
pET-14b vectors containing cDNAs encoding FGF1 and FGF2 and pET-M11 vector
containing FGF7 cDNA were as described (Xu et al., 2012); cDNAs encoding FGF3,
FGF10, FGF16, FGF17 and FGF20 were purchased from Eurofins Genomics (Ebersberg,
Germany); cDNA encoding FGF6, FGF8 and FGF22 were purchased from Life Technolo-
gies (Paisley, UK); cDNAs encoding HaloTag was acquired from Kazusa DNA Research
Institute (Kisarazu, Japan); Primers for PCRwere from Life Technologies (Paisley, UK). All
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Table 1 Peptide sequences of FGFs, the N-terminal HisTag constructs and the N-terminal HaloTag constructs. FGF names, sequences and amino
acid numbering are according to the UniProt entry. FGF1 is an N-terminal truncated protein (Ke et al., 1990). FGF2 does not possess a secretory
signal sequence, whereas there is no signal peptide recognised in Uniprot for FGF16 and FGF20; consequently full length protein sequence was
expressed. For all other FGFs, the protein expressed was without the Uniprot determined secretory signal sequence. FGFx refers any one of the FGFs.
TEV cleavage sites are in red.
Name UniProt accession
number
Residues in mature protein
FGF1 P05230 16–155
FGF2 P09038-2 1–155
FGF3 P11487 18–239
FGF6 P10767 38–208
FGF7 P21781 32–194
FGF8b P55075-3 23–215
FGF10 O15520 38–208
FGF16 O43320 1–207
FGF17 O60258-1 23–216
FGF20 Q9NP95 1–211
FGF22 Q9HCT0 23–170
HisTag terminus (pET-M11) MKHHHHHHPMSDYDIPTTENLYFQGA-[FGFx]
HaloTag and TEV site to conjoin
with FGF sequence
MPEIGTGFPFDPHYVEVLGERMHYVDVGPRDGTPVLFLHGNPTSSYV
WRNIIPHVAPTHRCIAPDLIGMGKSDKPDLGYFFDDHVRFMDAFIEAL
GLEEVVLVIHDWGSALGFHWAKRNPERVKGIAFMEFIRPIPTWDEWPE
FARETFQAFRTTDVGRKLIIDQNVFIEGTLPMGVVRPLTEVEMDHYREP
FLNPVDREPLWRFPNELPIAGEPANIVALVEEYMDWLHQSPVPKLLFWG
TPGVLIPPAEAARLAKSLPNCKAVDIGPGLNLLQEDNPDLIGSEIARWLS
TLEISGEPTTEDLYFQS-[FGFx]
of the protein sequences corresponding to the above cDNAs are listed in Table 1. Enzymes
for cloning were from: NcoI, BamHI and T4 ligase (NEB, Hitchin, UK); KOD Hot Start
DNA polymerase (Merck, Hertfordshire, UK); In-Fusion® HD Cloning Kit (Clontech,
Takara Bio Europe SAS, Saint-Germain-en-Laye, France). Bacterial cells: DH5α, BL21
(DE3) pLysS and SoluBL21 were a gift from Olga Mayans, University of Liverpool. The
sources of other materials were as follows: LB broth and LB agar (Merck, Hertfordshire,
Germany); Soniprep 150 Plus (MSE, London, UK); Aﬃ-Gel® Heparin Gel (Bio-Rad,
Hertfordshire, UK), CM Sepharose Fast Flow, DEAE Sepharose Fast Flow, HiTrap Q
HP column; empty disposable PD-10 Columns; A¨KTApurifier 100 plus (GE Healthcare,
Buckinghamshire, UK).
For cell culture the following materials were used: Dulbecco’s modified Eagle’s
medium (DMEM, Life Technologies), fetal calf serum (FCS, Labtech International
Ltd, East Sussex, UK), 7.5% (w/v) sodium bicarbonate (Invitrogen, Paisley, UK),
200 mM L-glutamine (Gibco), 5 µg/mL insulin (Sigma-Aldrich, Dorset, UK), 5 µg/mL
hydrocortisone (Sigma-Aldrich), bovine serum albumin (BSA; A7030, Sigma-Aldrich)
for cell culture, cell culture dishes (Corning, Nottingham, UK). For SDS-PAGE and
Western blotting: dried skimmed milk (Marvel, Spalding, UK), BSA (Fisher Scientific,
Lougborough, UK), protease inhibitor (Roche, Burgess Hill, UK), phospho-p44/42MAPK
(T202/Y204) antibody (Cell Signalling, NEB, Hitchin, UK), monoclonal β-actin antibody
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Figure 1 Cloning strategy for plasmids encoding Halo-FGFs. DNA encoding HaloTag was inserted 5￿
of the FGF2 coding sequence with the In-Fusion HD enzyme. Subsequently, a NotI cleavage site was
added 5￿ to the BamHI site and other FGFs were exchanged into the plasmid using the digestion-ligation
cloning method. A cartoon structure of Halo-FGF is presented in the middle of this figure.
(Sigma-Aldrich, Dorset, UK), anti-mouse IgG, horseradish peroxidase-linked antibody
(Cell Signalling, NEB), polyvinylidene fluoride (PVDF) transfer membrane (Millipore UK,
Hertfordshire, UK), enhanced chemiluminescence (ECL) Western blotting reagents (GE
Healthcare, Little Chalfont, UK), Hyperfilm (GEHealthcare, Little Chalfont, UK).
DNA cloning of hexahistidine tagged FGFs (His-FGFs) and
HaloTag tagged FGFs (Halo-FGFs)
DNA encoding FGF1, FGF3, FGF6, FGF8, FGF10, FGF16, FGF17, FGF20 and FGF22 was
cloned into pET-M11 such that the resulting protein would have a N-terminal 6xhis tag
followed by a tobacco etch virus (TEV) cleavage site (ENLYFQ). FGF2 and FGF7 DNA se-
quences were previously cloned into pET-14b and pET-M11, respectively (Xu et al., 2012).
A plasmid encoding Halo-FGF2 was produced by adding a HaloTag encoding
DNA sequence in-frame 5￿ to a DNA sequence encoding full-length FGF2. This
construct was then used to produce the other DNAs encoding Halo-FGFs (Fig. 1).
The plasmid pET-14b-fgf 2 contains NcoI and BamHI cleavage sites 5￿ and 3￿ of
fgf 2, respectively. This vector was linearized by digestion with NcoI. The DNA en-
coding HaloTag (Fig. 1: blue insert) was amplified by PCR using the Halo-FGF2-
Forward, AAGGAGATATA CCATGCCAGAAATCGGTACTG, and Halo-FGF2-Reverse,
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Table 2 Concentrations ofNaCl in 50mMTris-Cl buﬀer (pH7.4) used for heparin aﬃnity chromatog-
raphy of FGFs. [NaCl] for lysate is the concentration of NaCl in the sample applied to the column.
Name [NaCl] for lysate (M) [NaCl] for wash (M) [NaCl] for elution (M)
FGF1 0.6 0.6 1.0
FGF2 0.6 0.6 1.5
FGF3 0.3 0.6 1.0
FGF6 0.3 0.4 1.0
FGF7 0.3 0.3 1.0
FGF8 0.6 0.6 1.5
FGF10 0.6 0.6 1.0
FGF16 0.3 0.4 1.0
FGF17 0.6 0.6 1.0
FGF20 0.3 0.4 1.0
FGF22 0.6 0.8 1.5
TCCCGGCTGCCATGGAGCTCTGAAAGTACAGATC, primers (NcoI cleavage site
underlined), and inserted into the linearized vector using In-Fusion enzyme. A TEV
cleavage site (Fig. 1: green ellipsoid) was also included at the C-terminus of HaloTag to
allow release of the FGF. A NotI cleavage site was also inserted 5￿ of the BamHI to provide
an additional 3￿ cleavage sites for cloning. The other cDNAs (FGF1, FGF3, FGF6, FGF7,
FGF8, FGF10, FGF16, FGF17, FGF20 and FGF22) were exchanged into the established
pET-14b-Halo-fgf2 plasmid by double-digestion with NcoI and BamHI/NotI enzymes and
ligation using T4 ligase (Fig. 1).
Protein expression and purification of His-FGFs and Halo-FGFs
His-FGF7, because it is toxic like native FGF7 (Ron et al., 1993), was transformed into BL21
(DE3) pLysS (F– ompT hsdSB(rB–, mB–) gal dcm (DE3) pLysS (CamR)) for subsequent
protein expression and purification. FGF2, the other His-FGFs and Halo-FGFs were
transformed into SoluBL21(F– ompT hsdSB(rB–, mB–) gal dcm (DE3)). The bacteria
containing FGF encoding plasmids were cultured at 37 ◦C until the OD600 values
were between 0.4 and 0.6, and then protein expression at 16 ◦C was induced by adding
1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The bacteria were harvested by
centrifugation at 4 ◦C, 14,000 g for 10min and the pellets frozen at−80 ◦C.
The bacterial pellets were resuspended with the corresponding 50 mM Tris-Cl lysate
buﬀers (pH 7.4) (Table 2), and the cells were disrupted by 5–6 cycles of sonication
(30 s sonication, 60 s pause) on ice. Cell debris and insoluble proteins were removed by
centrifugation at 4 ◦C, 30,000 g for 30 min. Then, the presence of soluble FGFs was tested
by analysis of whole cells, the supernatant and pellet by separation of polypeptides on 12%
(w/v) SDS-PAGE and coomassie staining.
FGF2 and His-FGF7 were purified as described before (Xu et al., 2012). Soluble FGF1,
FGF2, FGF3, FGF10, FGF16 and FGF17, including His-FGFs and Halo-FGFs, were loaded
onto a 3 mL and the other soluble FGFs were loaded onto an 8 mL column of heparin
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agarose. For each FGF, diﬀerent concentrations of NaCl (in 50 mM Tris-Cl pH 7.4)
were used for washing and elution (Table 2) by following the previous measurements
on the electrolyte sensitivity of their heparin binding assessed by Western blot (Asada
et al., 2009). The yields of His-FGFs and Halo-FGFs were quantified by measuring the
absorbance at 280 nm and the level of impurities were estimated by analysis of coomassie
stained SDS-PAGE gels with ImageJ-Analyze-Gels (Ferreira & Rasband, 2012). The
soluble His-FGFs eluted from heparin aﬃnity chromatography were further purified
by Ni2+ aﬃnity chromatography. Due to the negative charge on the surface of HaloTag
and positive charge on the surface of FGFs, Halo-FGFs could bind to both cation- and
anion-exchange stationary phases. Thus, Halo-FGF1, Halo-FGF2, Halo-FGF3, Halo-FGF7
and Halo-FGF10 were purified by chromatography on a 5 mL HiTrap Q HP column.
Samples were applied in 0.15 M NaCl in PB buﬀer (2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4, pH 7.4) and eluted with a gradient running to 0.8 M NaCl in the
same buﬀer. Halo-FGF6 and Halo-FGF20 were purified by chromatography on a 3 mL
column of CM Sepharose Fast Flow followed by a 3 mL column of DEAE Sepharose Fast
Flow. Samples were again applied in 0.15MNaCl in PB buﬀer and eluted with 0.4 MNaCl
in the same buﬀer. The purified His-FGFs and Halo-FGFs were analysed by 12% (w/v)
SDS-PAGE followed by coomassie staining.
Purification of FGFs by removing HaloTag from Halo-FGFs
To test the accessibility of the TEV cleavage site, some Halo-FGFs, including Halo-FGF2,
Halo-FGF17, Halo-FGF6, Halo-FGF8 and Halo-FGF22 eluted with high concentration
of NaCl in 50 mM Tris buﬀer from heparin agarose chromatography and Halo-FGF20
purified with heparin, DEAE and CM chromatography, were incubated with 2.5%
(mol/mol) TEV protease at 4 ◦C overnight. In cases where the digestion products were
cloudy, they were clarified by centrifugation for 30 min at 13,000 g, 4 ◦C. Samples were
then analysed on a 12% (w/v) SDS-PAGE. The supernatants of the TEV digestions of
Halo-FGF6 and of Halo-FGF20 were applied onto a 2 mL heparin agarose column, and
washed as before (Table 2). FGF6 and FGF20 were eluted with PB buﬀer containing 1 M
NaCl or 0.1M arginine and 1MNaCl, respectively. After TEV digestion, FGF17 was further
purified on a 1 mL HiTrap SP HP cation-exchange column by washing with 0.3 M NaCl
and eluting with 1 M NaCl, both in 50 mM Tris-Cl, pH 7.4. All of the fractions from the
purification steps were analysed by 12% (w/v) SDS-PAGE.
Cell culture
Rama 27 cells were cultured in DMEM medium containing 10% (v/v) FCS, 4 mM
L-glutamine, 0.75% (w/v) sodium bicarbonate, 50 ng/mL insulin and 50 ng/mL hydro-
cortisone (Rudland, Twiston Davies & Tsao, 1984). HaCaT cells were cultured in the same
medium, but without insulin and hydrocortisone (Boukamp et al., 1988). Cell number was
measured with a Z1 coulter particle counter (Beckman Coulter, HighWycombe, UK).
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Measurement of p44/42MAPK phosphorylation
Cells were cultured in 3 cm dishes until near confluence. Then, the dishes were washed
twice with phosphate-buﬀered saline (PBS) and 2.5 mL step-down medium (SDM:
DMEM with 250 ng BSA, 0.75% (w/v) sodium bicarbonate and 4 mM L-glutamine)
was added for 24 h (Rama 27 cells) or 48 h (HaCaT cells). Rama 27 and HaCaT cells were
then incubated with diﬀerent FGFs for 15 min, as described in the figure legends. After
the incubation, the cells were washed twice with ice-cold PBS and collected by scraping
in 2X SDS-PAGE lysis buﬀer (4% (w/v) SDS, 20% (v/v) glycerol, 12% (v/v) Tris-Cl (pH
6.8), 2.5% (v/v) β-mercaptoethanol, 0.02% (w/v) bromophenol blue, 1 tablet of protease
inhibitor and 6.8 mL distilled water). The cell lysates were heated for 10 min at 98 ◦C prior
to SDS-PAGE.
Western blot
After separation by 10% (w/v) SDS-PAGE, polypeptides were transferred onto a PVDF
membrane. Themembrane was blocked with 5% (w/v) skimmedmilk in 1X TBST (50mM
Tris-Cl, 150 mM NaCl and 0.05% Tween-20 (v/v), pH 7.5) for 2 h. After two washes
with TBST, the membrane was incubated with phospho-p44/42MAPK antibody (1:1,000
dilution in TBST) on a shaker overnight at 4 ◦C. Secondary anti-mouse antibody (1:1,000
dilution) was added to the membrane after three washes with TBST, 5 min each, for 1 h
at room temperature. Following three washes with TBST to remove the excess secondary
antibody, the membrane was covered with 1mL ECL solution and signal was detected with
Hyperfilm. The same membrane was stripped with 2.5% (w/v) SDS in TBST at 50 ◦C for
1 h and reblocked as above, before probing with β-actin antibody (1:10,000 dilution). The
Western blot band intensity was quantified in the same way as SDS-PAGE bands and the
signal intensities of phospho-p44/42MAPK were normalised by dividing by the intensity of
the band corresponding to β-actin and then by that of the BSA control samples.
Cell growth assay
Cell growth in Rama 27 fibroblasts was measured as before (Smith, Winslow & Rudland,
1984). Rama 27 cells were dispensed into a 24 well cell culture plates at 2,000 cells/well.
After 24 h the cells were washed twice with PBS and cultured in SDM, as described for
the p44/42MAPK phosphorylation assay for 24 h. The SDM was then replaced and the
appropriate proteins added, as described in the figure legend. After 68 h incubation, cells
were trypsinised and the number of cells counted.
RESULTS AND DISCUSSION
Expression of soluble FGFs
Based on their relative expression and solubility properties, the FGFs were split into three
diﬀerent groups: FGFs that expressed well as soluble proteins (Group 1: FGF1, FGF2 and
FGF10), FGFs that expressed at a low level (Group 2: FGF3 and FGF7), and FGFs that were
insoluble when expressed in E. coli (Group 3: FGF6, FGF8, FGF16, FGF17, FGF20 and
FGF22).
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Group 1: soluble FGFs
After induction, bands corresponding to the expected molecular size of His-FGF1,
FGF2 and His-FGF10 were apparent in the whole cell lysates (Figs. 2A, 2C and 2E,
lane L, green arrow). His-FGF1 and His-FGF10 were expressed at a higher level than
FGF2 in E. coli SoluBL21. After centrifugation of the cell lysates, bands corresponding
to the molecular size of all three FGFs were mainly recovered in the soluble fraction
(supernatant), rather than in the insoluble fraction (pellet; Figs. 2A, 2C and 2E, lanes S
and P). Chromatography of the supernatants on heparin demonstrated that little of the
expressed protein was present in the flow-through fraction (Figs. 2A, 2C and 2E, lane T).
Weak bands corresponding to His-FGF1 and His-FGF10, but not FGF2, were observed
in the wash fraction (Figs 2A and 2E, lane Wa), which may represent aggregated or less
well-folded protein. The majority of the three FGFs was recovered in the high NaCl eluate
(Figs. 2A, 2C and 2E, lane Hep), which demonstrated that these soluble FGFs bound
heparin strongly. This indicated that they were likely to be properly folded, because the
canonical, highest aﬃnity heparin binding site of FGFs depends on the tertiary structure of
the proteins (Xu et al., 2012).
The bands corresponding to Halo-FGF1, Halo-FGF2 and Halo-FGF10 were clearly
observed in the whole cell lysates and these proteins were all highly expressed in SoluBL21
cells (Figs. 2B, 2D and 2F, lane L, red arrow). Similarly to the His-FGF1, FGF2 and
His-FGF10, after centrifugation of the whole cell lysates, the bands corresponding to
the three Halo-FGFs were observed in the soluble fractions (Figs. 2B, 2D and 2F, lanes
S and P). Chromatography of the soluble fractions on heparin indicated that most of
Halo-FGF2 andHalo-FGF10 had bound to the column, but there was a substantial amount
of Halo-FGF1 in the flow-through (Figs. 2B, 2D and 2F, lane T). This may be due to the
capacity of the column for Halo-FGF1 being lower than for His-FGF1. All three Halo-FGFs
were eluted from the heparin aﬃnity column at the expected NaCl concentration (Figs. 2B,
2D and 2F, lane Hep).
The yield of Halo-FGF1 and Halo-FGF10 was similar to that of the corresponding
his-tagged proteins (Table 3). However, since the Halo-FGF proteins are considerably
larger than the corresponding His-tagged FGF1 and FGF10, this represents a decrease in
themolar amounts of FGF produced. In contrast, the yield of Halo-FGF2 was 4-fold higher
(Table 3), which is only partly accounted for by the increased size of the fusion protein.
The low yield of full-length FGF2 has been ascribed to the presence of secondary structure
at the 5￿ end of the FGF2 mRNA (Knoerzer et al., 1989), and the presence of the upstream
HaloTag sequencemaymitigate this eﬀect.
Group 2: low expression proteins
The expression of His-FGF3 was weak, as was that of His-FGF7 (expressed in BL21 DE3
pLysS) due to its toxicity (Ron et al., 1993) (Figs. 3A and 3C, lane L, S and P, green arrow).
Heparin chromatography of the supernatants demonstrated that the yields of soluble
His-FGF3 andHis-FGF7 were quite low (Figs. 3A and 3C, lane Hep; Table 3).
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Figure 2 Expression and heparin aﬃnity purification of His-FGF1, FGF2, His-FGF10, Halo-FGF1,
Halo-FGF2 and Halo-FGF10. Following induction of expression with IPTG, cells were lysed by soni-
cation and the insoluble material collected by centrifugation. The supernatant was subjected to heparin-
aﬃnity chromatography and samples were then analysed by SDS-PAGE and coomassie staining. Lane
M, markers; L, sonicated whole cell lysate; P, pellet following centrifugation of lysate; S, corresponding
supernatant; T, unbound, flow-through fraction from heparin-aﬃnity chromatography; Wa, wash of
heparin-aﬃnity column (Table 2); Hep, high NaCl eluate of heparin-aﬃnity column (Table 2). Green
arrows: FGF or His-FGF; red arrows: Halo-FGF.
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Table 3 Summary of themolecular sizes and yields ofHis-FGFs andHalo-FGFs. The molecular weight
of the proteins was calculated from their amino acid sequence. The concentrations and volumes of His-
FGFs and Halo-FGFs recovered from heparin aﬃnity chromatography were measured. The impurities
identified by SDS-PAGE were quantified using ImageJ relative to the band corresponding to His-FGF and
toHalo-FGF and the amount of protein in the eluate from heparin chromatography adjusted accordingly,
to provide an estimate of the yield.
FGFs Molecular weight (kDa) Yield (mg/L)
HisTag HaloTag HisTag HaloTag
FGF1 19.1 50.9 14 16
FGF2 17.3
No Tag
52.2 2.5
No Tag
11
FGF3 28.2 60.0 0.5 11
FGF6 22.3 54.1 n.d.a 27
FGF7 22.2 54.0 0.6 5.6
FGF8 25.7 57.5 n.d.a 1.7
FGF10 22.7 54.5 7.7 9.3
FGF16 26.9 58.7 n.d.a 1.0
FGF17 25.8 57.6 n.d.a 1.5
FGF20 26.9 58.6 n.d.a 10
FGF22 20.5 52.3 n.d.a 2.0
Notes.
a Not detected. Insuﬃcient soluble protein for reliable quantification.
Transformation of SoluBL21with the plasmid encodingHalo-FGF7 yielded the expected
number of colonies, indicating that the fusion protein was not toxic. Bands corresponding
to the molecular size of Halo-FGF3 and Halo-FGF7 were observed in the cell lysates
(Figs. 3B and 3D, lane L, red arrow) and in the soluble fraction obtained after centrifu-
gation, whereas the pellet has relatively weaker bands (Figs. 3B and 3D, lanes P and S),
indicating that Halo-FGF3 and Halo-FGF7 were soluble. Heparin chromatography of the
soluble factions demonstrated that large amounts of Halo-FGF3 and Halo-FGF7 retained
their heparin binding interaction with the polysaccharide (Figs. 3B and 3D, laneHep).
The yields of Halo-FGF3 and of Halo-FGF7 were 21-fold and 9-fold greater than of the
corresponding His-tagged FGF (Table 3). Thus, the presence of the HaloTag N-terminal
fusion increased the amounts of FGF3 and FGF7 substantially, even after taking into
account the larger size of these fusion proteins (Table 3).
Group 3: insoluble proteins
His-FGF6, His-FGF8, His-FGF22, His-FGF17, His-FGF16 and His-FGF20 were all
expressed, albeit at diﬀerent levels. After centrifugation, bands corresponding to the
molecular sizes of these proteins were detected in the pellet (Fig. 4, compare lanes P
and S, green arrow). Although small amounts of protein, such as bands corresponding
to His-FGF6, His-FGF16 and His-FGF20, were observed in the supernatants (Fig. 4, lanes
S), no protein were detected in the eluate from heparin chromatography, which might
suggest these proteins were either small soluble aggregates or not properly folded. It has
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Figure 3 Expression and heparin binding-aﬃnity chromatography of His-FGF3, His-FGF7, Halo-
FGF3 and Halo-FGF7. Following induction of expression with IPTG, cells were lysed by sonication and
the insoluble material collected by centrifugation. The supernatant was subjected to heparin-afinity chro-
matography and samples were then analysed by SDS-PAGE and coomassie staining. Lane M, markers;
L, sonicated whole cell lysate; P, pellet following centrifugation of lysate; S, corresponding supernatant;
T, unbound, flow-through fraction from heparin-aﬃnity chromatography; Hep, high [NaCl] eluate of
heparin-aﬃnity column (Table 2). Green arrows: His-FGF; red arrows: Halo-FGF.
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Figure 4 Expression test of His-FGF6, His-FGF8, His-FGF22, His-FGF17, His-FGF16 and His-
FGF20. Following induction of expression with IPTG, cells were lysed by sonication and the insoluble
material collected by centrifugation. The whole cell lysate, supernatant and pellet were analysed by
SDS-PAGE and coomassie staining. Lane M, markers; L, sonicated whole cell lysate; P, pellet following
centrifugation of lysate; S, corresponding supernatant. Green arrows: His-FGF.
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been reported that FGF20 could also be solubilised by high concentrations of arginine
(Maity, Karkaria & Davagnino, 2009), which suggests that FGF20 in the lysis buﬀer has a
tendency to aggregate. However, arginine would compete for binding of FGFs to heparin,
which reduces the utility of this approach to solubilisation.
As illustrated by SDS-PAGE, all of the bands corresponding to the molecular size of
Halo-FGF6, Halo-FGF8, Halo-FGF22, Halo-FGF17, Halo-FGF16 and Halo-FGF20 were
clearly observed in the whole lysates, which suggested that all six proteins expressed well in
E. coli (Fig. 5, lanes L, red arrow), particularly Halo-FGF6, Halo-FGF17, Halo-FGF16
and Halo-FGF20. Although some material corresponding to the expected molecular
size of these Halo-FGFs was observed in the pellet after centrifugation of the cell lysates
(Fig. 5, lanes P), there were strong bands corresponding to Halo-FGF6, Halo-FGF16 and
Halo-FGF20 and weak bands corresponding to Halo-FGF8, Halo-FGF17 and Halo-FGF22
present in the soluble fractions (Fig. 5, lanes S). Following application to a heparin aﬃnity
column, most of Halo-FGF6 in the supernatant bound to heparin and was eluted by 1 M
NaCl in Tris-Cl (Fig. 5A, lanes S, T and Hep). Halo-FGF8 Halo-FGF17 and Halo-FGF22
also bound to the heparin-aﬃnity column reasonably eﬃciently, whereas a considerable
amount of Halo-FGF16 and Halo-FGF20 did not bind (Figs. 5B–5E, lanes S and T). All
four proteins could be recovered from heparin chromatography with high concentration
NaCl-containing elution buﬀers (Table 2) (Figs. 5B–5E, lane Hep). When the Halo-FGF20
in the flow-through fraction (Fig. 5F, lane T) was applied to a second heparin-aﬃnity
chromatography column, a large amount of Halo-FGF20 was found to bind and could
be eluted (Fig. 5F, lane Hep2). A considerable amount of Halo-FGF16 also failed to bind
to the heparin aﬃnity column (Fig. 5E, lane T), though the bound protein was eluted
with high NaCl (Fig. 5E, lane Hep). This suggests that the capacity of the heparin aﬃnity
column for Halo-FGF20 was exceeded. The same explanation may underlie the presence
of Halo-FGF16 in the flow-through fraction, though this protein was present at a slightly
lower level. However, nothing is known about the preference of either FGF16 or FGF20
for binding structures in the polysaccharide, if so these were relatively rare in heparin,
the column capacity might easily be exceeded. Alternatively, the Halo-FGF16 in the flow
through fraction may represent protein that is in small aggregates and/or not properly
folded.
Given that the amounts of soluble His-tagged FGF6, FGF8, FGF22, FGF17, FGF16
and FGF20 were not readily detectable, it is clear that the N-terminal HaloTag fusion
significantly improved the expression of soluble protein. The yield of Halo-FGF6 and
Halo-FGF20 was substantial (27 mg/L and 10 mg/L, respectively, Table 3). Although
a lower yield of Halo-FGF8, Halo-FGF16, Halo-FGF17 and Halo-FGF22 (1 mg/L to
2mg/L, Table 3) was obtained, it is nevertheless suﬃcient for many applications, including
microscopy. However, the heparin aﬃnity purification step did not produce entirely pure
protein, as judged by coomassie staining (Figs. 2, 3 and 5).
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Figure 5 Expression and heparin aﬃnity purification of Halo-FGF6, Halo-FGF8, Halo-FGF22, Halo-FGF17, Halo-FGF16 andHalo-FGF20. Fol-
lowing induction of expression with IPTG, cells were lysed by sonication and the insoluble material collected by centrifugation. The supernatant was
subjected to heparin-afinity chromatography and samples were then analysed by SDS-PAGE and coomassie staining. Lane M, markers; L, sonicated
whole cell lysate; P, pellet following centrifugation of lysate; S, corresponding supernatant; T, unbound, flow-through fraction from heparin-aﬃnity
chromatography; Hep, high NaCl eluate of heparin-aﬃnity column (Table 2). Red arrows: Halo-FGF.
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Further purification of some Halo-FGFs
Four Halo-FGFs, Halo-FGF1, Halo-FGF7, Halo-FGF6 and Halo-FGF20 were chosen to
determine whether the Halo-FGFs could be easily subjected to further purification, since
there was clear evidence for impurities following heparin-aﬃnity chromatography. Halo-
FGF1 and Halo-FGF7 were successfully purified by Q anion-exchange chromatography
(Figs. 6A and 6B, lane Q), which depends on the acidic isoelectric point of the HaloTag
(pI: 4.77). For Halo-FGF6 andHalo-FGF20, advantage was taken of the acidic HaloTag and
positive surfaces of FGFs, to enable a two-step ion-exchange purification of the eluate from
heparin-aﬃnity chromatography, using both DEAE anion and CM cation ion-exchange
chromatography (Figs. 6C and 6D, lane DEAE and CM). The isolated Halo-FGFs are
relatively pure, as is shown on the gels (Fig. 6).
Purification of FGFs by removing the HaloTag with TEV protease
The inclusion of a TEV site between the sequence of the HaloTag and FGF proteins
provides a means to remove the HaloTag fusion partner in those instances where the
HaloTag is not required for analysis (or when it may interfere with such analyses).
Halo-FGF2 was first incubated with TEV protease to test whether the fusion protein
could be cleaved by TEV. SDS-PAGE of the TEV digestion product of Halo-FGF2 shows
that almost all of the protein was cleaved into the 35 kDa HaloTag (Fig. 7A, red arrow) and
the 18 kDa FGF2 (Fig. 7A, green arrow). Thus, the cleavage site is fully accessible to TEV
protease. Both Halo-FGF17 and Halo-FGF20 were also well digested by TEV protease and
subsequently soluble FGF17 (Fig. 7B, green arrow) and FGF20 (Fig. 7C, green arrow) were
purified by cation-exchange and heparin chromatography, respectively.
Most of FGF6 (Fig. 7D, lane WDig, green arrow) and FGF22 (Fig. 7F, lane WDig, green
arrow) and a small proportion of FGF8 were also released fromHaloTag (Figs. 7D–7F, lane
WDig and S, red arrow), but these proteins were observed to aggregate upon cleavage. This
suggested that these proteins were not very stable, at least in the buﬀer conditions used
here, and required the HaloTag N-terminal fusion to remain soluble. The soluble FGF6
released by cleavage (Fig. 7D, lane S, green arrow) was applied to a heparin aﬃnity column,
but was observed to be concentrated at the top of the column where it formed a white
aggregate. Very little protein was eluted with 1MNaCl in PB buﬀer (Fig. 7D, lane E, green
arrow). The disappearance of FGF8 and FGF22 in the soluble fractions after TEV digestion
(Figs. 7E and 7F, lane S) showed that these two proteins were also not very soluble in the
present buﬀer conditions without the HaloTag fusion partner.
Biological activities of FGFs and Halo-FGFs on Rama 27 fibrob-
lasts and HaCaT keratinocytes
FGF1, FGF2 and FGF6 have a preference for FGFR1c (Zhang et al., 2006a), the
predominant receptor expressed by Rama 27 fibroblasts (Delehedde et al., 2000; Zhu et
al., 2010). When Rama 27 cells were stimulated with 25 pM FGF2 for 15 min, strong
bands corresponding to dually phosphorylated p44/42MAPK were apparent (Fig. 8A), as
observed previously (Delehedde et al., 2000; Zhu et al., 2010). Halo-FGF2 caused a similar
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Figure 6 Further purification of the heparin aﬃnity eluate ofHalo-FGF1,Halo-FGF6,Halo-FGF7 and
Halo-FGF20 by ion-exchange chromatography. The soluble Halo-FGF1 and Halo-FGF7 eluted from
heparin chromatography was purified using Q ion-exchange chromatography, while CM and DEAE
ion-exchange chromatography were used to purify Halo-FGF6 and Halo-FGF20. Lane M, markers; Hep,
eluate from heparin chromatography, Figs. 2A, 3D, 5A and 5F; T, unbound, flow-through fraction from
ion-exchange chromatography; Q, peak fractions collected from Q HP chromatography; DEAE eluate
from DEAE chromatography, two identical samples; CM, eluate from CM chromatography. Red arrows:
Halo-FGF.
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Figure 7 Cleavage of Halo-FGFs by TEV and purification. The eluates of Halo-FGF2, Halo-FGF17, Halo-FGF6, Halo-FGF8 and Halo-FGF22
from heparin-aﬃnity chromatography and the Halo-FGF20 purified by heparin and ion-exchange chromatography were digested by TEV protease
to separate the HaloTag and the FGF. Halo-FGF6, Halo-FGF8 and Halo-FGF22 became turbid after digestion and these samples were clarified
by centrifugation. Then, the samples containing FGF6 and FGF20 were subjected to heparin chromatography and that of FGF17 to SP HP
cation-exchange chromatography. Lanes M, markers; Hep, eluate from heparin chromatography; WDig, whole digestion product of Halo-FGFs
purified by heparin chromatography; T, unbound, flow-through fraction from heparin chromatography; Wa, wash of SP HP cation-exchange
chromatography; P, pellet following centrifugation of product of TEV digestion; S, supernatant after the centrifugation; E, high NaCl eluate of
heparin or SP cation-exchange chromatography. Green arrows: FGF; red arrows: HaloTag.
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Figure 8 Activities of FGFs on Rama 27 fibroblasts and HaCaT keratinocytes. Cells were grown in
3 cm diameter dishes (Western blots) or 24-well plates growth assay, as described in the Materials and
Methods. After incubation in SDM for 24 h (Rama 27) or 48 h (HaCaT), cells were stimulated with the
FGF protein for 15 min (Western blot) or 68 h (cell growth assay). (A) Stimulation of p44/42MAPK
phosphorylation by 25 pM HaloTag, FGF2, Halo-FGF2 and 50 pM HaloTag, FGF1, Halo-FGF1 and
Halo-FGF6 in Rama 27 fibroblasts. (B) Stimulation of p44/42MAPK phosphorylation by 500 pMHaloTag,
Halo-FGF8, Halo-FGF16, FGF17, Halo-FGF17, FGF20 and Halo-FGF20 in Rama 27 fibroblasts. (C)
Stimulation of cell growth of Rama 27 fibroblasts by 10 nM Halo-FGF16, FGF17 and Halo-FGF17. (D)
Stimulation of p44/42MAPK phosphorylation by 300 pMHis-FGF3, Halo-FGF3 and Halo-FGF22, 30 pM
His-FGF7, Halo-FGF7, His-FGF10 and Halo-FGF10 in HaCaT cells.
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Figure 9 Quantification of p44/42MAPK phosphorylation. The band intensities from two experiments
were quantified with imageJ and normalised to the BSA control to compare the similarities and diﬀer-
ences of stimulation of phosphorylation p44/42MAPK by diﬀerent FGFs. Results are the mean with the
actual values from two independent experiments.
stimulation of phosphorylation of p44/42MAPK (Fig. 8A). In contrast, the 25 pM or 50
pM HaloTag protein alone did not appreciably stimulate p44/42MAPK phosphorylation.
Therefore, the activity of Halo-FGF2 in this assay is equivalent to that of FGF2 (Fig. 9). In
the case of FGF1, the N-terminal HaloTag also did not aﬀect the ability of the growth factor
to stimulate the phosphorylation of p44/42MAPK (Fig. 8A). FGF6 is not soluble without
the HaloTag, so only the activity of the fusion protein could be tested, and it was found to
stimulate the phosphorylation of p44/42MAPK to an extent similar to that observed with
FGF1 and FGF2 (Fig. 8A). Since FGF6 has the same receptor preference as FGF1 and FGF2
(Zhang et al., 2006a), this suggests Halo-FGF6 was fully active.
FGF8, FGF16, FGF17 and FGF20 have a preference for FGFR3c, but they are also able
to activate FGFR1c, though higher concentrations of growth factor are required to elicit
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activity (Zhang et al., 2006a). When 500 pMHaloTag was added to the cells, there was no
detectable increase in phosphorylation of p44/42MAPK, whereas Halo-FGF8, Halo-FGF20
and FGF20 at concentrations comparable to those used in previous work (Zhang et al.,
2006a) were all found to stimulate the phosphorylation of p44/42MAPK (Fig. 8B). In
contrast, Halo-FGF16, Halo-FGF17 and FGF17 did not cause a detectable increase in
phosphorylation of p44/42MAPK (Fig. 9). These data indicate that Halo-FGF8, FGF20 and
Halo-FGF20 have biological activities on Rama 27 fibroblasts. The absence of stimulation
of phosphorylation of p44/42MAPK by Halo-FGF16 may reflect the fact that the ability
of this FGF to activate FGFR1c is considerably lower than that of FGF8, FGF17 and
FGF20 (Zhang et al., 2006a). However, the absence of stimulation of phosphorylation
of p44/42MAPK by FGF17 and Halo-FGF17 is more puzzling. One explanation may
be that FGF16, and perhaps FGF17, do not cause the FGFR to activate strongly early
biochemical signals that converge on p44/42MAPK. To test this, the capacity of Halo-FGF16,
Halo-FGF17 and FGF17 to stimulate cell growth was measured in Rama 27 fibroblasts.
The results show that 10 nM HaloTag only weakly stimulated the growth of Rama27
fibroblasts. Halo-FGF16 caused the number of cells to double compared to the negative
control, and this level was significantly (p = 0.015, Tukey test, OriginPro 9) above that
observed in the presence of HaloTag alone (Fig. 8C). Halo-FGF17 and FGF17 were even
more eﬀective, as they caused a 3- to 4-fold increase in the number of cells (Fig. 8C).
These results demonstrated that Halo-FGF16, FGF17 and Halo-FGF17 possess biological
activities of similar potency as observed by others in growth assays (Zhang et al., 2006a).
The activity of members of the FGF7 subfamily were tested on HaCaT keratinocytes,
as this cell type expresses the cognate receptor for these FGFs, FGFR2b (Ron et al.,
1993). HaCaT cells have previously been shown to express more p42MAPk than p44MAPk
(Delehedde et al., 2002). The data show clearly that HaloTag alone did not stimulate the
phosphorylation of p44/42MAPK (Fig. 8D). In contrast, FGF3, FGF7 and FGF10, and
the corresponding HaloTag fusion proteins stimulated p44/42MAPK phosphorylation
(Fig. 8C). FGF22, which is only soluble as a HaloTag fusion protein, also stimulated
p44/42MAPK phosphorylation to an extent similar to that seen with the other members of
the subfamily (Fig. 8D). Thus, these Halo-FGFs retain full biological activity in this assay.
CONCLUSION
In this study, we identified four useful properties of N-terminal HaloTag fusions for the
production of biologically active FGFs: (i) using the HaloTag can increase the yield of low
expression FGFs, (ii) the HaloTag rendered FGF7 non-toxic; (iii) for the insoluble FGFs,
the HaloTag enabled E.coli to express more soluble protein at low induction temperatures
and maintain solubility during isolation and storage; (iv) a consequence of the low
isoelectric point of HaloTag was that anion-exchange chromatography could be used
as an orthogonal step in the purification of the Halo-FGFs. However, there are clearly
limitations; for example, some of the FGFs did not retain solubility following cleavage from
the HaloTag. This may reflect the fact that no single solubilisation tag is a universal panacea
for resolving the problems of protein expression (Costa et al., 2014). Nevertheless, because
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the HaloTag can enhance expression of soluble protein and provide a means to label FGF
protein with diﬀerent fluorescent dyes and quantum dots, e.g., Los et al. (2008); Zhang et
al. (2006b) it is clearly a versatile and useful tool for these two purposes and, therefore,
worthwhile exploring as a part of experimental strategy with these aims.
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